Japan's Medical Insurance Agency Considers Lowering Combo Drug Prices
This article was originally published in PharmAsia News
Executive Summary
Japan's Drug Pricing Committee of the Central Medical Insurance Agency [Chuikyo] considered a proposal July 15 to revise the current pricing formula for combination drugs, and some angiotensin II receptor blockers combined with diuretics could see prices lowered by as much as 30 percent in Japan
You may also be interested in...
Novartis And Daiichi Sankyo Obtain Japanese Price Listings, May Set Precedent For Combination Re-pricing
Japan's Central Social Medical Insurance Agency, also called Chuikyo, recently approved price listings for Novartis' and Daiichi Sankyo's respective potential blockbuster combination diabetes drugs, and the council also agreed to review drug pricing policy to encourage investment in drug innovation
Novartis And Daiichi Sankyo Obtain Japanese Price Listings, May Set Precedent For Combination Re-pricing
Japan's Central Social Medical Insurance Agency, also called Chuikyo, recently approved price listings for Novartis' and Daiichi Sankyo's respective potential blockbuster combination diabetes drugs, and the council also agreed to review drug pricing policy to encourage investment in drug innovation
Japan’s Pharma Industry Proposes Plans To Reform Drug Pricing System
TOKYO - The Japanese pharmaceutical industry has been in talks with the government over an industry proposal on ways to better sustain the price of novel drugs released in the country